Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06047210 · ClinicalTrials.gov registry record
Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis
A clinical trial, sponsored by Swedish Orphan Biovitrum.
- Completed
- Registry status
- 14
- Enrollment target
NCT06047210 is a clinical trial that has completed, run by Swedish Orphan Biovitrum. The registered enrollment target is 14 participants.
The verdict
NCT06047210 has completed, sponsored by Swedish Orphan Biovitrum.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.
Interventions
- OTHER Blood Draws Data Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-12-14 |
| Est. Completion | 2019-10-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06047210
The ClinicalTrials.gov registry entry for NCT06047210 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Orphan Biovitrum, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood Draws Data Collection is the first listed.
NCT06047210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06047210 about?
NCT06047210 is a clinical study titled "Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis". This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.
What is the current status of trial NCT06047210?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2016-12-14. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT06047210?
The interventions under investigation include: Blood Draws Data Collection (OTHER).
Who is sponsoring clinical trial NCT06047210?
This trial is sponsored by Swedish Orphan Biovitrum, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.